Research information only, not medical advice. GHK-Cu (copper tripeptide-1) is not an FDA-approved drug for any human therapeutic indication. In topical/cosmetic form it is regulated as a cosmetic ingredient and sold over the counter; injectable and systemic use remains research-only or physician-supervised compounding. In 2026 the FDA/HHS signaled moving several peptides toward compounding eligibility.
GHK-Cu at a glance
As of June 2026 the human evidence is limited and concentrated on topical skin applications; most systemic data is preclinical. See the indexed studies below, graded by evidence level.
See also GHK-Cu vs BPC-157 .
Evidence profile
70 studies- Human trial 5 · 7%
- Review 18 · 26%
- Animal 13 · 19%
- In-vitro 26 · 37%
- Unknown 8 · 11%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Clinical trials
-
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
-
Topical GHK-Cu Gel for Acute Skin Wound Healing
-
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2025Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars
An open-label, single-arm interventional trial in women with acne scars reported that ThriveCo Scar Fader Gel with Scarcedeâ„¢ (containing copper tripeptide-1) significantly reduced scar appearance and improved skin texture over 45 days with no reported adverse effects.
- Human trial 2024An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults
A prospective, open-label, single-center study in adults reported significant 15-day improvements in dandruff, scalp hydration, and hair parameters using a hydroxy acid scrub plus a copper tripeptide-1 serum regimen, but it lacked randomization and a control group.
- Human trial 2026Glycyl-L-Histidyl-L-Lysine Copper Complex (GHK-Cu): A Hypothesis for the Modulation of Peri-Plexus Fibrosis in Chronic Brachial Plexus Injury Based on a 60-Day Observational Assessment
This observational study proposes a hypothesis for the modulation of peri-plexus fibrosis using GHK-Cu in chronic brachial plexus injury.
- Human trial 2026Glycyl-L-Histidyl-L-Lysine Copper Complex (GHK-Cu): A Hypothesis for the Modulation of Peri-Plexus Fibrosis in Chronic Brachial Plexus Injury Based on a 60-Day Observational Assessment
This 60-day observational study hypothesizes that GHK-Cu modulates peri-plexus fibrosis in chronic brachial plexus injury.
- Human trial 2026Glycyl-L-Histidyl-L-Lysine Copper Complex (GHK-Cu): A Hypothesis for the Modulation of Peri-Plexus Fibrosis in Chronic Brachial Plexus Injury Based on a 60-Day Observational Assessment
This preprint hypothesizes that GHK-Cu modulates peri-plexus fibrosis in chronic brachial plexus injury based on a 60-day observational assessment.
- Review 2026Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Review 2026Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- Review 2026Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Review 2026Smart Healing for Wound Repair: Emerging Multifunctional Strategies in Personalized Regenerative Medicine and Their Relevance to Orthopedics
- Review 2026Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
+ 60 more studies indexed for GHK-Cu.
Frequently asked questions
- Is GHK-Cu approved for human use?
- GHK-Cu (copper tripeptide-1) is not an FDA-approved drug for any human therapeutic indication. In topical/cosmetic form it is regulated as a cosmetic ingredient and sold over the counter; injectable and systemic use remains research-only or physician-supervised compounding. In 2026 the FDA/HHS signaled moving several peptides toward compounding eligibility.
- What does the research on GHK-Cu show?
- As of June 2026 the human evidence is limited and concentrated on topical skin applications; most systemic data is preclinical. See the indexed studies below, graded by evidence level.